Verastem
VSTMAlgoritmens signaler
- ›Starkt 3m-momentum (+71.4%)
- ›Starkt 6m-momentum (+67.0%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (76% årlig)
- ›+184% från 52v-botten
- ›Ökad handelsvolym (+159%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsVerastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance Singapore
2 h sedanVerastem, Inc. (VSTM) stock price, news, quote and history Yahoo Finance Singapore
Yahoo Finance SingaporeVSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes - Stocktwits
14 h sedanVSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes Stocktwits
StocktwitsVerastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
1 d sedanVerastem, Inc. (VSTM) Stock Price, News, Quote & History Yahoo! Finance Canada
Yahoo! Finance CanadaDoes Verastem (VSTM) Still Trade Near Fair Value On Sales? - Yahoo Finance
2 d sedanDoes Verastem (VSTM) Still Trade Near Fair Value On Sales? Yahoo Finance
Yahoo FinanceVerastem (VSTM) Stock Forum and Discussion - Moomoo
2 d sedanVerastem (VSTM) Stock Forum and Discussion Moomoo
MoomooMizuho raises Verastem stock price target on strong trial data - Investing.com
2026-10-15Mizuho raises Verastem stock price target on strong trial data Investing.com
Investing.comVerastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap? - Yahoo Finance
2026-10-15Verastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap? Yahoo Finance
Yahoo FinanceVerastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - Business Wire
2026-10-14Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Business Wire
Business WireVerastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
2025-11-14Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously anno
VerastemBusiness WireVerastem Oncology Announces Proposed Public Offering of Common Stock
2025-11-13Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell
VerastemBusiness WireVerastem Oncology to Present at Upcoming Investor Conferences
2025-11-05Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is schedu
VerastemBusiness WireVerastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
2025-11-04Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported fina
VerastemBusiness WireVerastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
2025-10-23Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouraging preliminary data from
VerastemBusiness WireVerastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
2025-10-23Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a confe
VerastemBusiness WireVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
2025-10-19Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and saf
VerastemBusiness WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-10-07Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purc
VerastemBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.